Chronic heart disease

Reading File

search_medical_text

chronic heart disease etiology pathophysiology classification diagnosis management

search_medical_image

chronic heart disease cardiac imaging echocardiography

GradeResponse

The retrieval was limited, so I'll supplement with comprehensive medical knowledge to deliver a thorough answer.

Chronic Heart Disease

"Chronic heart disease" broadly encompasses long-standing structural or functional cardiac conditions, most commonly chronic heart failure (CHF), coronary artery disease (CAD), chronic valvular disease, and chronic cardiomyopathies. Below is a comprehensive overview.

Classification

Category	Examples
Coronary Artery Disease (CAD)	Stable angina, prior MI, ischemic cardiomyopathy
Heart Failure	HFrEF (EF <40%), HFmrEF (EF 40–49%), HFpEF (EF ≥50%)
Cardiomyopathies	Dilated, hypertrophic, restrictive, arrhythmogenic
Valvular Heart Disease	Aortic stenosis/regurgitation, mitral stenosis/regurgitation
Congenital Heart Disease	Corrected or uncorrected structural defects persisting into adulthood
Hypertensive Heart Disease	Concentric LV hypertrophy, diastolic dysfunction

Etiology & Risk Factors

Modifiable:

Hypertension (most common cause of HFpEF)
Dyslipidemia, diabetes mellitus, obesity
Smoking, sedentary lifestyle
Alcohol use (dilated cardiomyopathy)

Non-modifiable:

Age, male sex, family history
Prior MI or cardiac surgery

Other:

Chagas disease (endemic cause in Latin America — a parasitic cardiomyopathy)
Autoimmune disorders (lupus, sarcoidosis, amyloidosis)
Chemotherapy-related cardiotoxicity (anthracyclines, trastuzumab)

Pathophysiology

Chronic heart disease typically involves a compensatory-then-decompensatory cascade:

Cardiac injury (ischemia, pressure/volume overload, toxin)
Neurohormonal activation: RAAS and sympathetic nervous system upregulation
Ventricular remodeling: hypertrophy, dilation, fibrosis
Reduced cardiac output → systemic and pulmonary congestion
End-organ damage: renal impairment, hepatic congestion, skeletal muscle wasting

Clinical Presentation

Symptoms (NYHA Classification):

NYHA Class	Description
I	No symptoms with ordinary activity
II	Mild symptoms, slight limitation with ordinary activity
III	Marked limitation; comfortable only at rest
IV	Symptoms at rest; unable to perform any activity without discomfort

Signs:

Dyspnea on exertion, orthopnea, PND
Peripheral edema, elevated JVP
S3 gallop (volume overload), S4 (stiff ventricle)
Displaced apical impulse (dilated cardiomyopathy)
Murmurs (valvular disease)
Pulmonary crackles

Diagnosis

Initial Workup

ECG: LVH, prior MI (Q waves), arrhythmias, LBBB
Chest X-ray: Cardiomegaly, pulmonary vascular congestion, pleural effusions, Kerley B lines
BNP / NT-proBNP: Elevated in HF (BNP >100 pg/mL suggestive; NT-proBNP >300 pg/mL)
Labs: CBC, BMP (eGFR, electrolytes), LFTs, TSH, fasting lipids, HbA1c, iron studies

Imaging Modalities

Modality	Key Role
Echocardiography	First-line: EF, wall motion, valvular function, diastolic parameters
Cardiac MRI (CMR)	Gold standard for chamber quantification, tissue characterization (fibrosis, edema, amyloid)
Cardiac CT (CCT)	Coronary anatomy, rule out CAD, pericardial disease
Nuclear (SPECT/PET)	Myocardial perfusion/ischemia, viability, amyloidosis (PYP scan)
Coronary angiography	Definitive assessment of CAD; pre-revascularization

Management

Non-Pharmacological

Salt restriction (<2 g/day in HF), fluid restriction if severe
Daily weight monitoring
Cardiac rehabilitation (Class I for stable CAD and HFrEF)
Exercise training, smoking cessation, alcohol abstinence

Pharmacological — HFrEF (EF <40%)

The "fantastic four" disease-modifying therapies (ACC/AHA/ESC guidelines):

Drug Class	Examples	Benefit
ACEi/ARB/ARNi	Ramipril, Losartan, Sacubitril-Valsartan	Reduce mortality ~20%; ARNi preferred over ACEi
Beta-blockers	Carvedilol, Metoprolol succinate, Bisoprolol	Reduce mortality ~35%
MRA (mineralocorticoid antagonist)	Spironolactone, Eplerenone	Reduce mortality in NYHA II–IV
SGLT2 inhibitors	Dapagliflozin, Empagliflozin	Reduce HF hospitalization and CV death regardless of diabetes status

Additional agents:

Diuretics (furosemide, torsemide): Symptom relief, not mortality benefit
Ivabradine: For HR ≥70 bpm on max beta-blocker; reduces hospitalization
Hydralazine + nitrates: In ACEi/ARB-intolerant patients (especially African Americans — A-HeFT trial)
Digoxin: Reduces hospitalization; no mortality benefit

Pharmacological — HFpEF (EF ≥50%)

SGLT2 inhibitors (Empagliflozin — EMPEROR-Preserved; Dapagliflozin — DELIVER): Reduce HF hospitalization
Control of comorbidities: BP, AF, obesity, diabetes
Diuretics for congestion
MRAs (Spironolactone — TOPCAT trial: modest benefit in Americas subgroup)

Device Therapy

Device	Indication
ICD	Primary/secondary prevention; EF ≤35%, NYHA II–III, on GDMT ≥3 months
CRT (biventricular pacing)	EF ≤35%, LBBB, QRS ≥150 ms, NYHA II–IV
CRT-D	Combination of CRT + ICD
Wearable cardioverter-defibrillator	Newly diagnosed cardiomyopathy awaiting GDMT response
LVAD	Bridge to transplant or destination therapy in advanced HF

Revascularization

PCI or CABG indicated for ischemic cardiomyopathy with viable myocardium and suitable anatomy
CABG preferred over PCI for multivessel CAD with diabetes (FREEDOM trial)

Complications

Arrhythmias: AF (most common), ventricular tachycardia/fibrillation — major cause of sudden cardiac death
Thromboembolic events: LV thrombus, stroke (especially with AF)
Cardiorenal syndrome: Worsening renal function secondary to low output or venous congestion
Cardiac cachexia: Muscle wasting in advanced HF
Sudden cardiac death (SCD): Risk highest in HFrEF with EF ≤35%
Pulmonary hypertension: Secondary to chronic left-sided failure

Prognosis

1-year mortality after hospitalization for HF: ~20–30%
5-year mortality: ~50% overall (worse than many cancers)
Predictors of poor prognosis: Low EF, elevated BNP, renal dysfunction, hyponatremia, NYHA IV, frequent hospitalizations
MAGGIC risk score and SHFM (Seattle Heart Failure Model) are validated tools for estimating prognosis

Monitoring

BNP/NT-proBNP: Serial measurement guides therapy titration
Echocardiography: Repeat at 3–6 months after initiating GDMT, then annually
Remote hemodynamic monitoring (CardioMEMS PA pressure sensor): Reduces HF hospitalizations in NYHA III patients (CHAMPION trial)
Renal function and electrolytes: Monitor closely on ACEi/ARB, MRA, SGLT2i

If you have a specific aspect of chronic heart disease you'd like to explore further (e.g., a particular cardiomyopathy, HFpEF vs. HFrEF in depth, specific drug mechanisms, or imaging findings), let me know.

Create a poster

Generating Image

I've reached the image generation limit for this session. Unfortunately, the poster couldn't be created due to a tool error on the first attempt and the budget being exhausted on the retry.

Here's what you can do to get the poster:

Use an AI image generator such as Adobe Firefly, Canva AI, or DALL·E via ChatGPT with this prompt:

"A professional medical educational poster about Chronic Heart Disease for a cardiology department. Central human heart illustration with labeled structures. Organized sections covering: types (CAD, HFrEF, HFpEF, Cardiomyopathy, Valvular Disease), risk factors (hypertension, diabetes, smoking, obesity), key symptoms (dyspnea, edema, fatigue), NYHA classification (Class I–IV), diagnosis methods (ECG, Echo, BNP, Chest X-ray), treatment (ACEi/ARNi, Beta-blockers, MRA, SGLT2 inhibitors, ICD/CRT devices), and complications (arrhythmias, SCD, cardiorenal syndrome). Clean clinical layout, blue and red color scheme, suitable for a hospital setting."

Use Canva (canva.com) with their medical poster templates and fill in the content from the comprehensive overview I provided above.

Would you like me to help structure the poster content into a layout outline or provide any other format?

This is a shared conversation. Sign in to Orris to start your own chat.